It has been found that radiotherapy can facilitate the release of interferon-beta (IFNβ) to upregulate B2M/MHC-I expression on resistant tumor cells, enhance antigen presentation, and restore responsiveness to PD-1 therapy (101). Here, B2M is linked to neoplasm.